Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Amantadine Therapy for Cognitive Impairment Related to Post-COVID Condition

NCT06055244 is registered in ClinicalTrials.gov with Ohio State University as lead sponsor.

NCT NCT06055244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06055244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Amantadine Therapy for Cognitive Impairment Related to Post-COVID Condition
Lead sponsor
Ohio State University
Phase
Phase 2
Overall status
Completed
Start date
December 7, 2023
Completion date
December 29, 2025
Enrollment
64 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

long covid, post-acute covid19 syndrome, post-covid19 condition